These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32420699)

  • 1. Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.
    Matsumura-Kimoto Y; Tsukamoto T; Shimura Y; Chinen Y; Tanba K; Kuwahara-Ota S; Fujibayashi Y; Nishiyama D; Isa R; Yamaguchi J; Kawaji-Kanayama Y; Kobayashi T; Horiike S; Taniwaki M; Kuroda J
    Cancer Med; 2020 Jul; 9(14):5185-5199. PubMed ID: 32420699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma.
    Shimura Y; Kuroda J; Ri M; Nagoshi H; Yamamoto-Sugitani M; Kobayashi T; Kiyota M; Nakayama R; Mizutani S; Chinen Y; Sakamoto N; Matsumoto Y; Horiike S; Shiotsu Y; Iida S; Taniwaki M
    Mol Cancer Ther; 2012 Dec; 11(12):2600-9. PubMed ID: 23012246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphoinositide-dependent protein kinase 1 is a potential novel therapeutic target in mantle cell lymphoma.
    Maegawa S; Chinen Y; Shimura Y; Tanba K; Takimoto T; Mizuno Y; Matsumura-Kimoto Y; Kuwahara-Ota S; Tsukamoto T; Kobayashi T; Horiike S; Taniwaki M; Kuroda J
    Exp Hematol; 2018 Mar; 59():72-81.e2. PubMed ID: 29287939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma.
    Isa R; Horinaka M; Tsukamoto T; Mizuhara K; Fujibayashi Y; Taminishi-Katsuragawa Y; Okamoto H; Yasuda S; Kawaji-Kanayama Y; Matsumura-Kimoto Y; Mizutani S; Shimura Y; Taniwaki M; Sakai T; Kuroda J
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
    Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
    Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of RSK2 influences the biological activities of human osteosarcoma cells through inactivating AKT/mTOR signaling pathways.
    Qiu Q; Jiang J; Lin L; Cheng S; Xin D; Jiang W; Shen J; Hu Z
    Int J Oncol; 2016 Jun; 48(6):2508-20. PubMed ID: 27082640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
    Cinar M; Hamedani F; Mo Z; Cinar B; Amin HM; Alkan S
    Leuk Res; 2013 Oct; 37(10):1271-7. PubMed ID: 23962569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel wiring of the AKT-RSK2 signaling pathway plays an essential role in cancer cell proliferation via a G
    Choi JS; Cho YY
    Biochem Biophys Res Commun; 2023 Jan; 642():66-74. PubMed ID: 36566564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
    Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
    Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
    Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
    Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p90 ribosomal S6 kinase 2 is associated with and dephosphorylated by protein phosphatase 2Cdelta.
    Doehn U; Gammeltoft S; Shen SH; Jensen CJ
    Biochem J; 2004 Sep; 382(Pt 2):425-31. PubMed ID: 15206906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1.
    Frödin M; Jensen CJ; Merienne K; Gammeltoft S
    EMBO J; 2000 Jun; 19(12):2924-34. PubMed ID: 10856237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting protein kinase C in mantle cell lymphoma.
    Rauert-Wunderlich H; Rudelius M; Ott G; Rosenwald A
    Br J Haematol; 2016 May; 173(3):394-403. PubMed ID: 26914495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
    Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
    Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.
    Stratford AL; Reipas K; Hu K; Fotovati A; Brough R; Frankum J; Takhar M; Watson P; Ashworth A; Lord CJ; Lasham A; Print CG; Dunn SE
    Stem Cells; 2012 Jul; 30(7):1338-48. PubMed ID: 22674792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRD4-Regulated Molecular Targets in Mantle Cell Lymphoma: Insights into Targeted Therapeutic Approach.
    Tsukamoto T; Nakahata S; Sato R; Kanai A; Nakano M; Chinen Y; Maegawa-Matsui S; Matsumura-Kimoto Y; Takimoto-Shimomura T; Mizuno Y; Kuwahara-Ota S; Kawaji Y; Taniwaki M; Inaba T; Tashiro K; Morishita K; Kuroda J
    Cancer Genomics Proteomics; 2020; 17(1):77-89. PubMed ID: 31882553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma.
    Romanchikova N; Strods A; Strazdina J; Strumfs B; Trapencieris P
    Anticancer Res; 2016 Nov; 36(11):6133-6140. PubMed ID: 27793942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.
    Ma J; Lu P; Guo A; Cheng S; Zong H; Martin P; Coleman M; Wang YL
    Br J Haematol; 2014 Sep; 166(6):849-61. PubMed ID: 24957109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribosomal S6 Kinase 2 (RSK2) maintains genomic stability by activating the Atm/p53-dependent DNA damage pathway.
    Lim HC; Xie L; Zhang W; Li R; Chen ZC; Wu GZ; Cui SS; Tan EK; Zeng L
    PLoS One; 2013; 8(9):e74334. PubMed ID: 24086335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting RSK2 in Cancer Therapy: A Review of Natural Products.
    Wu T; Chen Z; Liu X; Wu X; Wang Z; Guo W
    Anticancer Agents Med Chem; 2024 Sep; ():. PubMed ID: 39248063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.